Levy M
Dept. of Internal Medicine, Hadassah University Hospital, Jerusalem, Israel.
Agents Actions Suppl. 1988;25:21-31.
Over-the-counter (OTC) analgesics, i.e. aspirin, paracetamol, and dipyrone, continue to be the most widely used drug group. Recently, some non-steroidal anti-inflammatory drugs became available as OTC drugs. Our concern has persisted during the past decade in view of the following adverse effects: hepatotoxicity (including the drug aetiology of Reye's Syndrome), analgesic nephropathy, blood dyscrasias, gastrointestinal complications, and certain hypersensitivity reactions. Of particular interest are the identification of high risk groups and questions relating to geographical risk variations. Although the above adverse reactions are thought to be rare, the massive use of OTC analgesics requires quantitative estimates of the risk involved. What is needed is not only the relative risk, but an estimate of the excess risk of reactions in users. This is the parameter to be used in comparative evaluation of the public health hazard and the resulting regulatory action. Such data are generally lacking. A recent international population-based case-control study on the drug aetiology of agranulocytosis and aplastic anaemia is a rare example of such research. Unfortunately, on occasion the experience with that study has been that the provision of reassuring quantitative data is not a guarantee for scientifically based decisions in the face of heated pharmaco-political debates. Still, because government bodies do not foster the needed research, it remains for the pharmaceutical industry to assume the responsibility for continued pharmacoepidemiological assessment of the safety of OTC analgesics.
非处方(OTC)镇痛药,即阿司匹林、对乙酰氨基酚和安乃近,仍然是使用最广泛的药物类别。最近,一些非甾体抗炎药也成为了非处方药。鉴于以下不良反应,在过去十年中我们一直对此感到担忧:肝毒性(包括瑞氏综合征的药物病因)、镇痛性肾病、血液系统异常、胃肠道并发症以及某些过敏反应。特别值得关注的是高危人群的识别以及与地域风险差异相关的问题。尽管上述不良反应被认为很少见,但非处方镇痛药的大量使用需要对所涉及的风险进行定量评估。我们不仅需要相对风险,还需要估计使用者中反应的额外风险。这是用于比较评估公共卫生危害及后续监管行动的参数。而此类数据普遍缺乏。最近一项基于国际人群的关于粒细胞缺乏症和再生障碍性贫血药物病因的病例对照研究,是这类研究中罕见的一个例子。不幸的是,有时从该研究的经验来看,在激烈的药物政治辩论面前,提供令人安心的定量数据并不能保证做出基于科学的决策。尽管如此,由于政府机构不推动所需的研究,制药行业仍需承担起对非处方镇痛药安全性进行持续药物流行病学评估的责任。